       Document 2801
 DOCN  M94A2801
 TI    Treatment with thalidomide in AIDS patients.
 DT    9412
 AU    Klausner JD; Makonkawkeyoon S; Akarasewi P; Kasinrerk W; Nakata K;
       Kaplan G; NYU Med Cntr. Dept of Med., NY.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):221 (abstract no. PB0312). Unique
       Identifier : AIDSLINE ICA10/94369774
 AB    OBJECTIVES: To demonstrate that thalidomide reduces the toxic
       manifestations of tumor necrosis factor (TNF) and decreases HIV-1 viral
       burden in patients with AIDS. METHODS: In a randomized, double-blind,
       prospective study, 41 male patients with AIDS and 6 months of weight
       loss were given 300 mg of thalidomide or placebo nightly for 21 days.
       Baseline and serial weekly symptom scores, body weights, CD 4 counts and
       plasma for HIV-1 titers were obtained. RESULTS: Treated patients (n =
       16, mean age 32, 48% with tuberculosis (TB), median CD4 count = 34)
       reported an increased appetite and gained an average of 4.5% in body
       weight versus 0.9% (P < 0.01) in controls (n = 16, mean age 32, 45% with
       TB, median CD4 count = 36). Six (29%) patients on thalidomide developed
       a drug rash. CD4 counts did not change with therapy. P24 antigen titers
       were measurable in 5 patients and decreased in 3 patients on
       thalidomide. DISCUSSION AND CONCLUSIONS: Thalidomide increased appetite
       and produced weight gain in AIDS patients with wasting. There was no
       significant adverse effect on immunosuppression and its effect on HIV-1
       viral burden is forthcoming.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS/*DRUG THERAPY/
       MICROBIOLOGY  Adult  Appetite/DRUG EFFECTS  Double-Blind Method  Human
       HIV-1/ISOLATION & PURIF  Male  Prospective Studies
       Thalidomide/PHARMACOLOGY/*THERAPEUTIC USE  Treatment Outcome
       Tuberculosis/COMPLICATIONS  Tumor Necrosis Factor/*ANALYSIS  Weight
       Gain/DRUG EFFECTS  CLINICAL TRIAL  MEETING ABSTRACT  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

